Capricor Therapeutics, Inc. (CAPR, Financial), a biotechnology firm, experienced a significant stock drop of 5.02% as its price fell to $20.29 per share. The trading volume reached 610,475 shares, with a turnover rate of 1.34% and a volatility of 5.81%.
Recent financial results reported the company achieving revenues of $3.97 million, while net profit was at a loss of $11 million. Earnings per share were negative at $0.35, with a gross profit of $3.61 million, resulting in a price-to-earnings ratio of -22.89.
In terms of institutional ratings, all six institutions rated the stock as a buy, with no hold or sell recommendations. Within the biotech sector, which saw an overall decline of 3.38%, several related stocks showed varied performance. Revolution Medicines Inc., Ocean Biomedical Inc., and Quince Therapeutics, Inc. saw considerable gains. Meanwhile, Aditxt, Inc., Evogene Ltd., and Gri Bio, Inc. showed high turnover rates of 273.94%, 243.35%, and 197.62%, respectively. Stocks like Revolution Medicines Inc., Promis Neurosciences Inc., and Vaccinex, Inc. recorded notable volatility.
Capricor Therapeutics is a U.S.-based biotech company specializing in developing leading-edge therapies for diseases, with a focus on Duchenne muscular dystrophy and other conditions. Their product pipeline includes CAP-1002 for Duchenne muscular dystrophy and COVID-19, CDC-Exosomes (CAP-2003), and Exosome-mRNA vaccines.
